Área salud
Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab
Late-onset neutropaenia is defined as an absolute neutrophil count of 4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed […]